Sign inCreate account

Report workspace tools

NCT04542941COMPLETEDanonymous

Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial

Sponsor

Source record

Makerere University

Phase

Source record

NA

Modality

AI-normalized

protein therapy

Target

AI-normalized

COVID Convalescent Plasma

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVID Convalescent Plasma

Source & freshness

Source record

NCT ID

NCT04542941

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2021

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04542941

Title

Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial

Sponsor

Makerere University

Status

COMPLETED

Phase

NA

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

COVID antiviral

Modality normalized

protein therapy

Target raw

COVID Convalescent Plasma

Target normalized

COVID Convalescent Plasma

Interventions

COVID Convalescent Plasma

Public preview

Source record

Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial is a NA clinical asset sponsored by Makerere University in Covid19. SEO and diligence focus: COVID Convalescent Plasma, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04542941

Status

COMPLETED

Phase

NA

Sponsor

Makerere University

Executive brief

Investment-Ready Snapshot

Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial is a NA clinical asset sponsored by Makerere University in Covid19. SEO and diligence focus: COVID Convalescent Plasma, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 15, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04542941

Indication

Covid19

Modality

protein therapy

Target

COVID Convalescent Plasma

Intervention

COVID Convalescent Plasma

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.